KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Finished Goods (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Finished Goods for 15 consecutive years, with $144.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Finished Goods rose 1.06% to $144.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $144.5 million, a 1.06% increase, with the full-year FY2025 number at $144.5 million, up 1.06% from a year prior.
  • Finished Goods was $144.5 million for Q4 2025 at Halozyme Therapeutics, down from $161.6 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $164.9 million in Q2 2025 to a low of $25.8 million in Q4 2021.
  • A 5-year average of $82.1 million and a median of $61.1 million in 2023 define the central range for Finished Goods.
  • Biggest YoY gain for Finished Goods was 200.99% in 2021; the steepest drop was 16.39% in 2021.
  • Halozyme Therapeutics' Finished Goods stood at $25.8 million in 2021, then soared by 78.28% to $46.0 million in 2022, then soared by 52.12% to $69.9 million in 2023, then soared by 104.41% to $142.9 million in 2024, then rose by 1.06% to $144.5 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Finished Goods are $144.5 million (Q4 2025), $161.6 million (Q3 2025), and $164.9 million (Q2 2025).